(thirdQuint)An Equivalence Study of Generic Ingenol Mebutate Gel 0.

015% and Picato Gel 0.

015% in Subjects With Actinic Keratosis.

 Picato(R) (ingenol mebutate) gel is the first and only ingenol mebutate product approved by the Food and Drug Administration (FDA) in 2012 for the topical treatment of AKs on the face and scalp (0.

015% formulation) and on the trunk and extremities (0.

05% formulation).

 The FDA approved regimen for ingenol mebutate gel, 0.

015% for the treatment of AKs on the face and scalp is once-daily application of one unit dose tube for three consecutive days applied to one contiguous skin area of approximately 25 cm2 (e.

g.

, 5 cm x 5 cm).

.

 An Equivalence Study of Generic Ingenol Mebutate Gel 0.

015% and Picato Gel 0.

015% in Subjects With Actinic Keratosis@highlight

The objective of this study was to evaluate the safety and therapeutic equivalence of generic ingenol mebutate gel, 0.

015% to Picato gel, 0.

015% by establishing the therapeutic comparability of the two active products and the superiority of the two active products over the vehicle gel in the treatment of AK on the face and scalp.

